Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Boehringer Ingelheim
Johnson and Johnson
Baxter
McKinsey

Last Updated: February 20, 2020

DrugPatentWatch Database Preview

Litigation Details for Senju Pharmaceutical Co. Ltd. v. Lupin Limited (D. Del. 2011)


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Senju Pharmaceutical Co. Ltd. v. Lupin Limited (D. Del. 2011)

Docket   Start Trial Date Filed 2011-03-31
Court District Court, D. Delaware Date Terminated 2013-08-09
Cause 35:271 Patent Infringement Assigned To Sue Lewis Robinson
Jury Demand Defendant Referred To Judge Mary Pat Thynge
Parties ALLERGAN INC.; HI-TECH PHARMACAL CO. INC.; KYORIN PHARMACEUTICAL CO. LTD.; LUPIN LIMITED; LUPIN PHARMACEUTICALS INC.; SENJU PHARMACEUTICAL CO. LTD.
Patents 4,551,456; 4,980,470; 5,880,283; 6,333,045
Attorneys Anuj K. Wadhwa; Brian P. Murray; Deanne M. Mazzochi; Harven DeShield; Jack B. Blumenfeld; John C. Phillips , Jr.; John D. Polivick; Maryellen Noreika; Megan C. Haney; Paul Molino; Tara Ragahavan; William A. Rakoczy
Link to Docket External link to docket
Small Molecule Drugs cited in Senju Pharmaceutical Co. Ltd. v. Lupin Limited
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Senju Pharmaceutical Co. Ltd. v. Lupin Limited (D. Del. 2011)

Date Filed Document No. Description Snippet Link To Document
2011-03-31 1 United States Patent No. 6,333,045 (“the ‘045 Patent”) and United States Patent No. 5,880,283 (“the ‘283 … Allergan has listed the ‘045 Patent, the ‘283 Patent, and other patents in the “Approved Drug Products…283 Patent”) under 35 U.S.C. §27l(e)(2) and declaration of infringement of those same patents THE PARTIES…interest in the ‘045 Patent. 22. Allergan is the exclusive licensee of the ‘045 Patent for ophthalmic uses…Claim l of the ‘283 Patent claims gatifloxacin sesquihydrate. A copy of the ‘283 Patent is attached to this External link to document
2012-12-07 135 infringement of U.S. Patent Nos. 6,333,045 ("the '045 patent") and 5,880,283 ("the '…#39;045 patent as reexamined. (D.I. 33) The next alleged infringement of the '045 patent as reexamined…invalidity in one patent action operates to bar relitigation of the validity of the same patent in a subsequent…Judgment on the Pleadings that the Claims of U.S. Patent No. 6,333,045 Are Invalid and Not Infringed. Signed…part, as follows: 1. Background. This patent infringement litigation was initiated on March External link to document
2012-12-14 137 infringement of U.S. Patent Nos. 6,333,045 ("the '045 patent") and 5,880,283 ("the '…granted, as follows: 1. Background. This patent infringement litigation was initiated on March …#39;283 patent") by defendants' Abbreviated New Drug Application ("ANDA") No. 202…202-653. 1 (D.I. 1) The '045 patent is directed to aqueous liquid pharmaceutical compositions comprising…reexamination of claims 1-3, 6, 8 and 9 of the '045 patent. (D. I. 10 at~~ 47-48) Defendants filed External link to document
2013-04-12 173 United States 24 patent 6,333,045 that we'll call the '045 patent. And this …off, the '470 prior art patent. This is 22 the patent that discloses gatifloxacin…prior 10 art '456 patent. This is one of the patents that discloses 11 literally…Honor, in the Patent Office, 22 and then told them somehow that this was patentable. …what this 11 patent at JTX-1 relates to? 12 A. This patent is about the improvement External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Johnson and Johnson
Express Scripts
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.